John is a 35-year-old male recently diagnosed with moderate-to-severe atopic dermatitis. He has no significant past medical history and is not on any chronic medications. His dermatologist has prescribed lebrikizumab 250 mg subcutaneously. John expresses concern about self-injection and asks whether using an autoinjector instead of a prefilled syringe would affect the medication’s effectiveness or safety.

Question: Based on current evidence regarding lebrikizumab administration, what is the best pharmacist response to John’s concern about using an autoinjector versus a prefilled syringe?

Maria is a 42-year-old female with moderate-to-severe atopic dermatitis prescribed lebrikizumab 250 mg subcutaneously. She is concerned about injection site pain and asks if the injection location (abdomen, arm, or thigh) will affect how well the medication works or its safety.

Question: What advice should the pharmacist provide regarding the impact of injection site on lebrikizumab pharmacokinetics and tolerability?

David is a 50-year-old man with moderate-to-severe atopic dermatitis starting lebrikizumab therapy. He is hesitant about self-injection due to fear of adverse reactions. He asks the pharmacist if using an autoinjector increases the risk of serious adverse events compared to a prefilled syringe.

Question: How should the pharmacist address David’s concerns about the safety of lebrikizumab administration via autoinjector versus prefilled syringe?